source
- FDA staff say Replimune's melanoma trial fails to demonstrate efficacyFDA staff reviewing Replimune's pivotal melanoma study concluded that the trial design did not provide sufficient evidence that the RP1 therapy works. The assessment was issued ahead of a schedule…
- GSK CEO outlines £1.9bn cost-saving drive and aims to launch 20 Phase 3 trials by year-endGSK chief executive Luke Miels presented a three‑year plan to make the company more agile and generate significant cost efficiencies. The strategy targets £1.9 billion in annual savings by 2029, wi…